A groundbreaking new vaccine has been registered in New Zealand, offering hope to older adults, particularly Māori, Pasifika, and those over the age of 60, in the fight against Respiratory Syncytial Virus (RSV). Developed over a span of 50 years, this vaccine aims to provide protection against RSV-associated lower respiratory tract disease, a condition that has posed a significant threat to vulnerable populations.
RSV, a highly contagious respiratory virus, has long been recognized as a serious health concern, predominantly affecting children but also posing risks to older adults. Despite being commonly associated with cold and flu-like symptoms, RSV can lead to severe illness and, in some cases, even fatalities among the elderly. Data reveals that individuals aged 60 and above experience a substantial burden of RSV-related hospitalizations and deaths in high-income countries.
Individuals with underlying chronic conditions such as asthma, diabetes, chronic obstructive pulmonary disease (COPD), and congestive heart failure face an increased risk of hospitalization due to RSV compared to those without such conditions. Moreover, Māori, Pasifika, and individuals residing in lower socioeconomic areas are disproportionately affected by the disease, facing a higher likelihood of hospitalization.
Arexvy, the world’s first RSV vaccine designed for older adults, has received approval for use in several countries, including Australia, the UK, the European Union, the US, Canada, and Japan. Clinical trials have demonstrated that the vaccine exhibits an impressive overall efficacy of 82.6% against RSV-Lower Respiratory Tract Disease (LRTD). Notably, a remarkable 94.6% efficacy rate was observed in adults aged 60 and above with underlying health conditions such as heart disease or diabetes, the demographic most susceptible to severe RSV-related complications.
While Arexvy represents a significant advancement in RSV prevention, it is important to acknowledge that, like other vaccines, it may not offer complete protection to all recipients. Given the urgency of addressing RSV ahead of the winter season, the vaccine underwent expedited review and was granted priority assessment during the registration process in New Zealand. Additionally, a funding application for Arexvy has been submitted to Pharmac for evaluation.
Brett Marett, the Medical Director of GSK NZ, emphasized the significance of the vaccine’s registration in New Zealand, underscoring the critical role it plays in safeguarding older adults from RSV. Marett expressed optimism about the vaccine’s potential to make a meaningful impact in protecting vulnerable populations against this previously unpreventable respiratory infection.
